Calcium phosphate cements (CPCs) have excellent biocompatibility and osteoconductivity for dental, craniofacial, and orthopedic applications. This article reviews recent developments in stem cell delivery via CPC for bone regeneration. This includes: (1) biofunctionalization of the CPC scaffold, (2) co-culturing of osteoblasts/ endothelial cells and prevascularization of CPC, (3) seeding of CPC with different stem cell species, (4) human umbilical cord mesenchymal stem cell (hUCMSC) and bone marrow MSC (hBMSC) seeding on CPC for bone regeneration, and (5) human embryonic stem cell (hESC) and induced pluripotent stem cell (hiPSC) seeding with CPC for bone regeneration. Cells exhibited good attachment/proliferation in CPC scaffolds. Stem-cell-CPC constructs generated more new bone and blood vessels in vivo than did the CPC control without cells. hUCMSCs, hESC-MSCs, and hiPSC-MSCs in CPC generated new bone and blood vessels similar to those of hBMSCs; hence, they were viable cell sources for bone engineering. CPC with hESC-MSCs and hiPSC-MSCs generated new bone two-to three-fold that of the CPC control. Therefore, this article demonstrates that: (1) CPC scaffolds are suitable for delivering cells; (2) hUCMSCs, hESCs, and hiPSCs are promising alternatives to hBMSCs, which require invasive procedures to harvest with limited cell quantity; and (3) stem-cell-CPC constructs are highly promising for bone regeneration in dental, craniofacial, and orthopedic applications.
tial public-health need (Shi et al., 2002; Mao et al., 2006; Mikos et al., 2006; Jiang et al., 2009; Rios et al., 2011; Rosa et al., 2012) . Approximately 600,000 bone graft procedures are performed each year in the United States, and about 2.2 million such procedures are performed worldwide annually (Marino and Ziran, 2010) . In the majority of cases, either autografts or allografts are performed (Marino and Ziran, 2010) . Although autografts are considered the gold standard, risks of donor site morbidity and limited availability restrict their applications. Allografts are impeded by potential infection and a high non-union rate with the host tissues. Therefore, tissue engineering with the combination of biomaterials and stem cells is being investigated as a promising alternative (Baksh et al., 2007; Mao et al., 2007; Abukawa et al., 2009; Huang, 2010; Ye et al., 2011; Luo et al., 2012) . Calcium phosphate (CaP) biomaterials are useful for bone repair due to their similarity to bone minerals (Leach et al., 2006; Zhao et al., 2009; Park et al., 2014) . Calcium phosphate cements (CPCs) are biocompatible, resorbable, osteoconductive, and injectable. The first CPC was developed in 1986 and consisted of a mixture of tetracalcium phosphate [TTCP, Ca 4 (PO 4 ) 2 O] and dicalcium phosphate anhydrous (DCPA, CaHPO 4 ) (Brown and Chow, 1986) . Because of its excellent biocompatibility and ability to be replaced by new bone, CPC has been approved by the Food and Drug Administration (FDA) for the repair of craniofacial defects (Friedman et al., 1998) . Since then, other CPC formulations have also been investigated (Barralet et al., 2002; Bohner et al., 2005; Ruhe et al., 2006; Bodde et al., 2009; Ginebra et al., 2010) . Several CPCs have been commercialized and applied in various clinical situations, such as cranioplasty, bone augmentation, implant fixation, fracture, and vertebroplasty (Chow, 2000; Jansen et al., 2005; Bohner, 2010; Ginebra et al., 2012) . Besides orthopedic applications, dental and craniofacial applications of CPC could include mandibular and maxillary ridge augmentation, major reconstructions of the maxilla or mandible after trauma or tumor resection, and supporting metal dental implants or augmentation of deficient implant sites.
The present review focuses on the combination of CPC scaffolds with stem cells for bone regeneration. A review such as this cannot cover the vast number of meritorious publications on various formulations of CPCs and their in vitro properties and in vivo performance. The reader is referred to comprehensive review articles in this field (Chow, 2000; Bohner et al., 2005; Jansen et al., 2005; Xu et al., 2008; Bohner, 2010; Ginebra et al., 2010 Ginebra et al., , 2012 Sugawara et al., 2013) . This article reviews recent work on stem cell seeding with CPC for bone tissue engineering, biofunctionalization of the CPC scaffold to enhance cell attachment and proliferation, the seeding of CPC with different stem cell species including human bone marrow mesenchymal stem cells (hBMSCs), human umbilical cord mesenchymal stem cells (hUCMSCs), human embryonic stem cells (hESCs), and human induced pluripotent stem cells (hiPSCs), and their in vivo bone regeneration behavior in animal models. These relatively new topics have not been addressed in previous reviews on CPC.
cPc biOfunctiOnAlizAtiOn With EnhAncED cEll rEsPOnsE
The success of cell seeding not only depends on cell seeding techniques and scaffold structure, but also closely relates to the capability of scaffold material to favor cell attachment and proliferation. Human stem cell attachment to traditional CPCs was relatively poor because of the ion activities of the cement. The addition of bioactive signals such as proteins or peptides is frequently used to enhance cell affinity in various biomaterials. Cell membrane receptors can recognize and bind to these biochemical cues presented in CPC, which in turn can activate cellular signal pathways able to tune gene expression and control cell fate. Thein-Han et al. (2012) compared the effects of 5 types of biofunctional agents to mediate the interactions between hUCMSCs and CPC. The first type was Arg-Gly-Asp (RGD) peptide, a well-known integrin-recognition site to promote cell attachment, with advantages of simple synthesis, minimal cost, low immunogenic activity, relative stability, and tight control of conformation. The second type was fibronectin (Fn), a cell adhesion molecule and an extracellular matrix (ECM) protein.
The third type is Fn-like engineered protein polymer (FEPP), a genetically engineered protein. The fourth type was Geltrex, a three-dimensional basement membrane ECM. The fifth type was human platelet concentrate, which contains many bioactive factors. Each agent was added to the liquid phase of CPC, then mixed with CPC powder and set to form a scaffold. hUCMSCs were seeded onto CPC scaffolds. Substantially enhanced cell attachment, proliferation, and ostegenic differentiation were achieved on biofunctionalized CPC compared with a CPC control. The CPC-RGD, CPC-Fn, and CPC-Platelets groups had the best cell response ( Fig. 1) (Thein-Han et al., 2012) . In addition, the CPC-Platelets group had the best osteogenic differentiation (Thein-Han et al., 2012) . In other studies, collagen (Pérez and Ginebra, 2013) , osteocalcin, and O-phospho-L -serine (Vater et al., 2010) were incorporated into CPC. In addition, surface treatment techniques, such as plasma treatment, were used to immobilize bioactive molecules on CPC/polymer scaffolds for the benefits of increased wettability, roughness, and porosity to further boost cellular response (He et al., 2013) .
cO-culturing OstEOblAsts/EnDOthEliAl cElls tO PrEvAsculArizE cPc
The reconstruction of large skeletal defects is a major challenge because of inadequate vascularization. A slow or incomplete vascularization at the defect where the scaffold was implanted in vivo would lead to inadequate oxygen and nutrition supply and waste products removal, thus causing hypoxia and cell death. Therefore, angiogenesis in bone tissue constructs and the development of a functional microvasculature are vital to achieve successful therapeutic outcome in bone regeneration. Recently, a macroporous CPC was prevascularized in vitro by the co-culture of human umbilical vein endothelial cells (hUVECs) and human osteoblasts (hOBs) (Thien-Han and Xu 2013; Chen et al., 2014) . For fabrication of the scaffold, chitosan was grafted with RGD, and the chitosan-RGD liquid was mixed with CPC powder to biofunctionalize the CPC. hUVECs and hOBs were co-cultured on macroporous CPC-RGD, and on CPC control without RGD, for up to 42 days. Immunostaining with endothelial marker showed that the quantity of microcapillary-like structures on CPC increased with time ( Figs. 2A, 2B ). At 42 days, the cumulative vessel length for the CPC-RGD scaffold was 1.69-fold that of the CPC control ( Fig. 2C ). Scanning electron microscopy (SEM) examination confirmed the morphology of self-assembled microcapillary-like structures on the CPC scaffold ( Fig. 2D ) (Chen et al., 2014) . These results demonstrated the promise of generating a prevascularized network on a macroporous CPC scaffold for potential enhancement of in vivo vascularization and bone regeneration.
sEEDing Of cPc With DiffErEnt stEM cEll sPEciEs hBMSCs are known for their ability to differentiate into different mesenchymal cell types, including osteoblasts, chondrocytes, and adipocytes. hBMSCs are considered the gold-standard cell source for bone tissue engineering research (Baksh et al., 2007; Mao et al., 2007) . hBMSCs attached well to surfacemodified CPCs (Vater et al., 2010; He et al., 2013) . They exhibited an elongated, spindle-shaped morphology with active filopodial protrusions to adhere to CPC (Vater et al., 2010; He et al., 2013) . hBMSCs populated and permeated the inside of porous CPCs, and higher porosity yielded better cell response (He et al., 2013) . Cells seeded on various CPCs successfully underwent osteogenic differentiation (Vater et al., 2010; He et al., 2013) . However, hBMSCs generally have several disadvantages, including the need for an invasive procedure to harvest, a relatively small MSC amount from each procedure, and loss of potency in hBMSCs from seniors and patients with diseases and disorders. Therefore, other sources of stem cells need to be explored for tissue engineering applications.
hUCMSCs are harvested from umbilical cords and represent an inexpensive and non-invasive cell source. hUCMSCs have robust proliferation and self-renewal capability, and a high plasticity and developmental flexibility owing to their origin in neonatal tissues (Bailey et al., 2007; Baksh et al., 2007; Xu et al., 2010; Zhao et al., 2010) . When seeded on the RGD-grafted macroporous CPC, hUCMSCs demonstrated good cell viability, proliferation, osteogenic differentiation, and mineral synthesis similar to that of hBMSCs (Chen et al., 2013a) . These studies indicated that hUCMSCs are a potent alternative to the goldstandard hBMSCs. Several factors were found to affect the cellular response of hUCMSCs to CPCs: (1) Surface chemistry. Besides surface modification by the aforementioned bioactive molecules, the addition of collagen fibers into CPC also enhanced hUCMSC attachment, osteogenic differentiation, and bone mineral synthesis (Thein-Han and (2) Surface area. The incorporation of submicron electrospun poly(D,L-lactide-coglycolide) (PLGA) fibers increased the surface area and enhanced hUCMSC proliferation, osteogenic differentiation, and mineralization (Bao et al., 2011). (3) Cell seeding density. Varying the cell seeding density is another strategy to optimize the cell-biomaterial microenvironments and osteogenic signal expression via different paracrine signal distances. The seeding of hUCMSCs onto the CPC scaffold at approximately 2,654 cells/mm 2 yielded a high percentage of live cells, fast proliferation, and high bone marker expression and mineralization (Zhou et al., 2011) . Besides hBMSCs and hUCMSCs, stem cells derived from dental tissues, such as dental pulp stem cells (DPSCs) and deciduous teeth stem cells (DTSCs) with the property to form a calcified matrix, also showed promising results for the regeneration of mineralized tissues in combination with CPCs (Xia et al., 2013) . hucMsc AnD hbMsc sEEDing On cPc fOr bOnE rEgEnErAtiOn in vivo Strategies for the acceleration of bone regeneration via CPC include the addition of bioactive agents such as osteocalcin, O-phospho-L -serine (Vater et al., 2010) , and bioactive glass (Yu et al., 2013) . Another strategy for the enhancement of bone regeneration is to combine stem cells with CPC (Zeng et al., 2012; Zou et al., 2012; Chen et al., 2013a) . With critical-sized cranial defects in rats Leach et al., 2006) , when hUCMSCs and hBMSCs were seeded onto a CPC scaffold and implanted into the defects, new bone formation increased with time (Figs. 3A-3F) (Chen et al., 2013a) . New bone started from the defect peripherals at the interface between the implant and native bone. Then, more new bone was gradually generated along CPC surfaces and inside the CPC scaffold (Chen et al., 2013a) . Compared with CPC control without cells, 88% and 57% increases in new bone were achieved when hBMSCs and hUCMSCs were seeded with CPC, respectively ( Fig. 3G) (Chen et al., 2013a) . At a higher magnification (Fig. 4) , the new bone appeared to be in the maturing process at 24 wk, manifested by the appearance of osteoid with osteocytes and blood vessels, and with newly formed bone being lined by osteoblasts. CPC resorption could be noticed in defects, with osteoclast-like multinuclear giant cells present at the internal surfaces of the macropores in CPC (Fig. 4B) (Chen et al., 2013a) . In summary, the least new bone was seen in the CPC control group, with more new bone formed in the hUCMSC and hBMSC groups than in the control group (p < .05), and there was no statistically significant difference between the hUCMSC and hBMSC groups (p > .1) (Chen et al., 2013a) .
In a rabbit maxillary sinus floor elevation model, seeding of CPC with hBMSCs generated greater new bone area than in a model without cells (Zeng et al., 2012) . These results suggest that the transplanted stem cells indeed participated in and contributed to osteogenesis. Initially, the seeded cells directly deposited bone matrix minerals in the scaffold. Then, via cellmediated paracrine simulation, the recruited native cells from the host tissues, including but not limited to osteoblast progenitors, endothelial cells, and osteoclasts, took over the responsibility of subsequent bone formation and remodeling (Wang et al., 2014) . Studies showed that the secretion of bioactive molecules by the seeded cells enabled the cell-CPC constructs to have bone-forming ability even in ectopic sites of nude mice, thus changing the osteoconductive CPC to become osteoinductive (Wang XJ et al., 2011) . In addition, prominent angiogenesis was observed in cell-seeded CPCs in vivo. Chen et al. (2013a) reported that the seeding of hBMSCs and hUC-MSCs with CPC resulted in 20% and 15% increases in blood vessel density, respectively. Furthermore, the addition of stem cells was reported to accelerate the degradation of CPC and could thus help balance the catabolism and anabolism of bone remodeling (Zeng et al., 2012; Wang et al., 2014) . In a canine peri-implant bone defect model, the application of the BMSC/ BMP-2/bFGF/CPC construct demonstrated the highest level of new bone apposition, followed by BMSC/BMP-2/CPC and BMSC/bFGF/CPC, which were still higher than BMSC/CPC, while CPC without cells had the least new bone (Wang L et al., 2011) .
usE Of hEscs With cPc fOr bOnE tissuE EnginEEring
Besides the use of hBMSCs and hUCMSCs, hESCs are an exciting cell source for regenerative medicine applications (Hwang Arpornmaeklong et al., 2009; Smith et al., 2010) . hESCs are relatively homogenous, possess a high self-renewal activity, have nearly unlimited proliferation capability, and can be differentiated into all cell types in the body. A recent study investigated the use of hESCs with CPC for osteogenic differentiation (Chen et al., 2013b) . hESCs were cultured to form embryoid bodies (EBs), and then, in further culture, MSCs were migrated out of the EBs. Flow cytometry evaluation indicated that the hESC-derived MSCs (hESC-MSCs) expressed the surface antigen profile typical of MSCs and were negative for typical hematopoietic and endothelial cell markers (Chen et al., 2013b) . When seeded onto CPC scaffolds, hESC-MSCs were differentiated into the osteogenic lineage, expressing high levels of osteogenic markers including alkaline phosphatase, osteocalcin, collagen I, and Runx2 (Chen et al., 2013b) .
In an animal study, hESC-MSCs were seeded, for the first time, onto CPC for bone regeneration in critical-sized cranial defects in rats. Four groups were tested: (1) CPC control without cells; (2) CPC with hESC-derived MSCs ("CPC+hESC-MSC");
(3) CPC with hESC-MSCs and 30% human platelet concentrate (hPC) ("CPC+hESC-MSC+30%hPC"); and (4) CPC+hESC-MSC+50%hPC. The hESC-MSCs on CPC had successful osteogenic differentiation, and new bone was generated in vivo (Fig.  5A) . Calcified new bone area fraction was plotted in Fig. 5B , and new blood vessel density was plotted in Fig. 5C (mean ± SD; n = 6). Seeding hESC-MSCs onto the CPC scaffold generated more new bone than in the CPC control (p < .05). The incorporation of hPCs into the CPC-hESC-MSC construct further increased new bone generation (p < .05). The groups containing hESC-MSCs and hPCs had new bone about threefold, and blood vessel density 1.6-fold, those of the CPC control.
usE Of hiPscs With cPc fOr bOnE tissuE EnginEEring
hiPSCs represent a major breakthrough in stem cell research and provide an invaluable resource for regenerative medicine (Takahashi and Yamanaka, 2006; Nakagawa et al., 2008; Amabile and Meissner, 2009; Ye et al., 2011; Villa-Diaz et al., 2012) . hiPSCs provide a promising method for obtaining patient-specific stem cells for tissue engineering. hiPSCs are believed to be very similar to hESCs in many respects, including the expression of certain stem cell genes and proteins, doubling time, chromatin methylation patterns, embryoid body formation, teratoma formation, viable chimera formation, potency, and differentiability (Takahashi and Yamanaka, 2006; Nakagawa et al., 2008) . Furthermore, hiPSCs possess nearly unlimited potential to proliferate and differentiate into all derivatives of the 3 primary germ layers (ectoderm, endoderm, and mesoderm) (Amabile and Meissner, 2009 ). In addition, hiPSCs can be easily and autogeneically accessible, thus avoiding both the ethical and immunological concerns related to hESCs. In a recent study, hiPSCs were cultured to derive MSCs (hiPSC-MSCs), after which hiPSC-MSCs underwent bone morphogenic protein 2 (BMP2) gene modification and were seeded onto CPC for the first time (Liu et al., 2013) . hiPSC-MSCs were infected with green fluorescence protein (GFP-hiPSC-MSCs) or BMP2 lentivirus (BMP2-hiPSC-MSCs). BMP2-hiPSC-MSCs expressed much higher BMP2 levels than hiPSC-MSCs. After 14-day culture in osteogenic medium, the ALP activity of BMP2-hiPSC-MSCs on CPC was 1.8 times that of the hiPSC-MSC control, indicating that the BMP2 gene transduction of hiPSC-MSCs enhanced the osteogenic differentiation. Osteocalcin gene expression of BMP2-hiPSC-MSCs on CPC was 2.3 times that of the hiPSC-MSC control. Bone matrix mineralization by BMP2-hiPSC-MSCs on CPC was 1.8 times that of the hiPSC-MSC control at 21 days (Liu et al., 2013) . These in vitro results indicated that CPCs seeded with hiPSC-MSCs are promising for bone tissue engineering.
In vivo bone regeneration of hiPSC-MSC-seeded CPC constructs was investigated, for the first time, in a criticalsized cranial defect model in rats. Four groups were tested: hiPSC-MSC-seeded CPC, hUCMSCseeded CPC, hBMSC-seeded CPC, and CPC control without cells. Histological H&E staining showed that the hiPSC-MSC and hUCMSC groups had nearly complete osseous bridging of the critical-sized defect, especially on the dura side at 12 wk, where the new bone had an organized pattern and mature bone morphology. The new bone area fraction for the hiPSC-MSC group was 30.4 ± 5.8%, 2.8-fold the 11.0 ± 6.3% for the CPC control (p < .01) (Fig. 6A) . No significant differences were detected among the 3 groups with stem cells (p > .05). New blood vessels were present in the new bone and the fibrous tissue filling the defects. New blood vessel densities of the hiPSC-MSC, hUCMSC, and hBMSC groups were significantly higher than that of the CPC control (p < .05). New blood vessel density of the hiPSC-MSC group was 1.7-fold that of the CPC control. Therefore, iPSC-MSCs appeared to have excellent osteogenic and angiogenic capabilities similar to those of hBMSCs and hUCMSCs. These results show that hiPSCs are promising for bone regeneration applications and that CPC is a biocompatible and resorbable scaffold suitable for delivering stem cells for craniofacial and orthopedic repairs. cOnclusiOns CPC scaffolds have high potential in a wide range of dental, craniofacial, and orthopedic applications due to their excellent biocompatibility, osteoconductivity, and resorbability. The present article reviewed new developments in stem cell seeding and delivery with CPC scaffolds, biofunctionalization of CPC to enhance cell attachment and proliferation, the seeding of CPC with different stem cell species including hBMSCs, hUCMSCs, hESCs, and hiPSCs, and their in vivo properties. While hBM-SCs are considered the gold standard for stem cell-based bone regeneration research, their drawbacks include the need for an invasive procedure to harvest hBMSCs and the limited cell quantity. hUCMSCs, hESCs, and hiPSCs have been demonstrated to be potent alternative cell sources to hBMSCs for bone regeneration. When seeded onto CPC scaffolds, these cells exhibited good attachment, proliferation, and osteogenic differentiation. When implanted into cranial defects in rats, stem cell-seeded CPC constructs generated much greater amounts of new bone and blood vessels compared with the CPC control without cells. Seeding of CPC with hUCMSCs, hESC-MSCs, and hiPSC-MSCs generated new bone and blood vessels similar to those of hBMSCs, indicating that these cells are promising viable cell sources for bone tissue engineering. For example, CPC constructs seeded with hESC-MSCs and hiPSC-MSCs generated new bone amounts two-to three-fold that of the CPC control. Therefore, the seeding of CPC scaffolds with stem cells is highly promising for the enhancement of bone regeneration in dental, craniofacial, and orthopedic applications. figure 6. Bone regeneration via stem cell seeding in CPC in cranial defects in rats. Four groups were tested: CPC with hiPSC-MSCs; CPC with hUCMSCs; CPC with hBMSCs; and CPC control without cells. (A) New bone area fraction at 12 wk (mean ± SD; n = 6). (b) New blood vessel density at 12 wk (mean ± SD; n = 6). The hiPSC-MSC group had new bone nearly three-fold, and blood vessel density 1.7-fold, those of the CPC control.
